PULMONARY ARTERIAL HYPERTENSION DRUG MARKET ANALYSIS

Pulmonary Arterial Hypertension Drug Market Size and Trends

The Global Pulmonary Arterial Hypertension Drug Market is estimated to be valued at USD 8.10 Billion in 2024 and is expected to reach USD 11.92 Billion by 2031, exhibiting a compound annual growth rate (CAGR) of 5.7% from 2024 to 2031.

Key Takeaways of the Pulmonary Arterial Hypertension Drug Market:

• Based on drug class, the Prostacyclin and Prostacyclin Analogs segment is expected to contribute the highest share of the market with 35.1% in 2024
• Based on route of administration, the oral segment is expected to contribute the highest share of the market with 36.3% in 2024
• Based on type, the branded drugs segment is expected to contribute the highest share of the market with 53.4% in 2024
• North America is expected to top the global market with 40.3% share, followed by Asia Pacific with 30.5% share in 2024

Market Overview:

There has been a steady rise in disease awareness among patients and healthcare providers. Additionally, new drug approvals and emerging treatment opportunities have expanded the market size. Several pharmaceutical companies such as Amgen Inc. have strong pipelines with novel drug molecules, which once approved will further drive the market growth during the forecast period. Furthermore, increasing research collaborations between industry players and research institutions for pulmonary hypertension is anticipated to contribute to the market expansion.

To learn more about this report, Request sample copy

Key Developments:

• In March 2024, the U.S. FDA approved OPSYNVI (macitentan and tadalafil), the first once-daily combination therapy for pulmonary arterial hypertension (PAH), based on positive Phase 3 A DUE study results. It expands Johnson & Johnson’s PAH portfolio, addressing all guideline-recommended pathways.
• In March 2024, Merck, a leading science and technology company, announced the U.S. FDA approval of WINREVAIR (sotatercept-csrk), the first activin signaling inhibitor for pulmonary arterial hypertension (PAH). The therapy improves exercise capacity, WHO functional class, and reduces clinical worsening risks, marking a new class of treatment for PAH. WINREVAIR previously received Breakthrough Therapy Designation.
• In August 2023, Keros Therapeutics, a clinical-stage biopharmaceutical company focused on hematological and musculoskeletal disorders, presented positive Phase 2 trial results for KER-012, showcasing its potential efficacy in treating pulmonary arterial hypertension
• In May 2023, Janssen, a subsidiary of Johnson & Johnson and a global innovator in healthcare solutions, submitted a new drug application to the USFDA for its combination therapy of tadalafil 40mg and macitentan 10mg for pulmonary arterial hypertension treatment
• In April 2023, Mochida Pharmaceutical, a Japan-based leader in pharmaceutical and healthcare innovations, launched its Treprost inhalation solution for pulmonary arterial hypertension, introducing the drug to the Japanese pulmonary arterial hypertension drug market.

Top Strategies Followed by Global Pulmonary Arterial Hypertension Drug Market Players

• Established Players: Leading companies in the pulmonary arterial hypertension drug market prioritize extensive research and development to innovate high-performance products
  • For instance, United Therapeutics has developed Tyvaso DPI, an inhaled treprostinil therapy for PAH, which received USFDA approval in May 2022
• Mid-Level Players: Mid-sized companies focus on delivering quality, budget-friendly products targeting price-sensitive consumers. For example, Gilead Sciences offers generic versions of its PAH drug, Letairis (ambrisentan), making treatment more accessible.
• Small-Scale Players: Small players often target niche markets with unique products. Aerovate Therapeutics focused on developing AV-101, an inhaled dry powder formulation for PAH, though it faced setbacks in clinical trials. Forming partnerships with local manufacturers facilitates market entry.
  • For instance, Reata Pharmaceuticals collaborated with local distributors to market bardoxolone methyl for PAH in specific regions

Emerging Startups - Pulmonary Arterial Hypertension Drug - Industry Ecosystem

• Innovative Technologies: Several startups are working on bioelectronic medicines. Volitron aims to develop implantable pacemaker-like devices that use electrical pulses to regulate pulmonary blood flow. Others, like Entropic, focus on AI platforms to predict treatment responses and tailor drug regimens. These emerging technologies could enable more individualized care approaches.
• Sustainable Solutions: Startups create eco-friendly options. Phospho3 applies green chemistry principles to develop plant-based medications with reduced waste. Meanwhile, Proxiad uses agricultural byproducts in novel drug delivery hydrogels to lower material costs. Their innovations may set standards for sustainability in clinical settings.
• Market Contribution: Niche startups focus on addressing unmet needs. Enopace specializes in regenerative therapies targeting vascular remodeling in pediatric patients. Similarly, HeartBio collaborates with insurers to offer home monitoring devices, improving healthcare accessibility. By partnering with providers and major life sciences companies, these startups drive innovative solutions that expand treatment options and improve patient outcomes.